IDH1 and glioblastoma: Survival data from patients who received a heterogenous mixture of treatment regimens (chemotherapy or radiation therapy or combination of chemotherapy with radiation therapy, with or without surgical resection), from the two largest TCGA cohorts (Affymetrix n1 = 496, Agilent n2 = 523, Fig. 3A) illustrated a better overall survival outcome for Proneural/Neural (previously defined by IDH-mutant and younger patient age, which were reported to have better prognosis4) versus Mesenchymal GBM (p < 0.05).